Dynavax Technologies Corporation (DVAX)
Chart Events
Performance Outlook
| Previous Close | 9.62 |
| Open | 9.56 |
| Bid | 11.08 x 800 |
| Ask | 11.09 x 1800 |
| Day's Range | 9.56 - 11.28 |
| 52 Week Range | 7.26 - 21.39 |
| Volume | |
| Avg. Volume | 2,545,832 |
| Market Cap | 1.337B |
| Beta (5Y Monthly) | 1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.34 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.25 |
- Motley Fool
Why Dynavax Stock Won on a Losing Monday for the Market
Although optimists currently believe we're getting past the worst of the coronavirus pandemic, Dynavax Technologies (NASDAQ: DVAX) shares saw a lift Monday on positive vaccine news. A popular coronavirus stock in the worst days of the outbreak, an important business partner of the company had some good regulatory news to impart. Dynavax investors took this to heart by pushing their company's stock up by nearly 2.3% on the day, while the S&P 500 index sank by 0.4%.
- PR Newswire
Dynavax to Present at the H.C. Wainwright Global Investment Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.
- PR Newswire
Independence Realty Trust Set to Join S&P MidCap 400; Alpha and Omega Semiconductor & Dynavax Technologies to Join S&P SmallCap 600
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:
